中际旭创(300308.SZ):拟发行可转债募资额由不超30亿元调至不超27.748亿元
格隆汇 3 月 9日丨中际旭创(300308.SZ)公布,公司第四届董事会第九次会议决议,审议通过了《关于调整公司向不特定对象发行可转换公司债券方案的议案》;
结合公司向不特定对象发行可转换公司债券项目深圳证券交易所的问询、项目的推进情况以及公司投资计划的实际情况,经慎重考虑,董事会根据股东大会的授权,对此次可转换公司债券方案中的此次发行募集总额从不超过人民币30亿元(含30亿元)调整为不超过人民币27.748亿元(含人民币27.748亿元)。公司独立董事发表了明确同意的独立意见。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.